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Abstract
Rhodococcus equi is an important pathogen of foals that causes severe pneumonia. To date, there is no licensed vaccine
effective against R. equi pneumonia of foals. The objectives of our study were to develop an electron beam (eBeam)
inactivated vaccine against R. equi and evaluate its immunogenicity. A dose of eBeam irradiation that inactivated replication
of R. equi while maintaining outer cell wall integrity was identified. Enteral administration of eBeam inactivated R. equi
increased interferon-c production by peripheral blood mononuclear cells in response to stimulation with virulent R. equi and
generated naso-pharyngeal R. equi-specific IgA in newborn foals. Our results indicate that eBeam irradiated R. equi
administered enterally produce cell-mediated and upper respiratory mucosal immune responses, in the face of passively
transferred maternal antibodies, similar to those produced in response to enteral administration of live organisms (a
strategy which previously has been documented to protect foals against intrabronchial infection with virulent R. equi). No
evidence of adverse effects was noted among vaccinated foals.
Citation: Bordin AI, Pillai SD, Brake C, Bagley KB, Bourquin JR, et al. (2014) Immunogenicity of an Electron Beam Inactivated Rhodococcus equi Vaccine in Neonatal
Foals. PLoS ONE 9(8): e105367. doi:10.1371/journal.pone.0105367
Editor: Roy Martin Roop, East Carolina University School of Medicine, United States of America
Received May 29, 2014; Accepted July 18, 2014; Published August 25, 2014
Copyright:  2014 Bordin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper and its
Supporting Information files.
Funding: This work was supported by the Morris Animal Foundation (D13EQ-0001). Additional funding was provided by the Link Equine Research Endowment,
Texas A&M University. AIB was supported by a fellowship from Fort Dodge Animal Health/Pfizer Animal Health (now Zoetis). An unrestricted gift from Boehringer-
Ingelheim to the Equine Infectious Disease Laboratory at Texas A&M University provided partial support to this project. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: AIB’s salary was supported by a fellowship from Fort Dodge Animal Health/Pfizer Animal Health (now Zoetis). The Morris Animal
Foundation and Link Equine Research Endowment sponsored this study, and additional support provided by an unrestricted gift from Boerhinger-Ingelheim.
None of the agencies or companies listed above had any role or influence in the data collection, data analysis, interpretation of results, or conclusions reported in
this manuscript; none of these companies have reviewed the manuscript. Moreover, none of the authors were employed in any way (including consultancy) by
any of the companies listed above. The authors declare no affiliation to products, patents, etc. related to this work with any company, including those listed
above. This support does not alter our adherence to PLOS ONE policies on sharing data and materials. FNO is employed by Antech Diagnostics; however, FNO was
not paid for his services and provided assistance outside of his work at Antech Diagnostics. Relevant to this work, FNO has no competing interests relating to
employment, consultancy, patents, products in development, etc. The authors declare no other competing financial interests.
* Email: ncohen@cvm.tamu.edu
Introduction
Rhodococcus equi is a facultative intracellular pathogen recog-
nized clinically as a leading cause of severe pneumonia in foals [1–
4]. To date, an efficacious vaccine against R. equi for foals is
lacking and there is no approved vaccine for foals against R. equi
in North America. Although a variety of strategies have been
evaluated for vaccination against R. equi (including immunization
of mares [5–9], inactivated R. equi administered parenterally to
foals or mice [7,10], sub-unit vaccines [8,9,11], DNA vaccines
[12,13], and live, mutant vaccines [14,15]), oral administration of
live, virulent R. equi is the only vaccination strategy that has been
demonstrated repeatedly to protect foals against experimental
intrabronchial challenge with virulent R. equi [16–18]. However,
the administration of live, virulent organisms is not considered an
acceptable strategy for vaccination of foals at horse breeding farms
because of concerns for environmental dissemination and the
potential to cause disease in some foals.
Inactivated bacteria and viruses can elicit protective immune
responses against systemic infections, including those of the
respiratory tract [19–22]. Electron beam (eBeam) irradiation is a
technology for microbial inactivation that is currently used for
sterilization and pasteurization [23–26]. Electron beam irradiation
at appropriate doses can be used to inactivate large volumes of
microbial cultures or to sterilize materials such as medical devices
[27–29], and has advantages relative to heat or formalin
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inactivation. Inactivation with either heat or formalin is known to
denature proteins, including immunogenic epitopes on the cell
surface [30,31]. More importantly, formalin is widely recognized
as resulting in incomplete inactivation of organisms, and has been
associated with vaccine-associated disease resulting from inade-
quate inactivation [32]. Thus, there is need for a reliable method
of microbial inactivation that will retain the bacterial cell structure
as similar as possible to a live organism for use in producing
vaccines. We therefore identified a dose of eBeam irradiation that
would inhibit bacterial replication while maintaining outer
membrane integrity of R. equi, and examined the immunogenicity




All procedures for this study were reviewed and approved by the
Texas A&M University Institutional Animal Care and Use
Committee (protocol number AUP# 2011-124) and the Texas
A&M University Institutional Biosafety Committee (permit
number 20110183-Cohen). The foals used in this study are owned
by Texas A&M University, and permission for their use was
provided in compliance with the Institutional Animal Care and
Use Committee procedures.
Preparation of bacteria and electron beam irradiation
Rhodococcus equi strain EIDL 5-331 (a virulent isolate from a
Texas foal) was used for this study. One colony-forming unit
(CFU) was inoculated into 50 ml of brain-heart infusion (BHI)
broth and shaken for 24 h at 37uC, sub-cultured in 1000 ml of
BHI broth and shaken for 24 h at 37uC. The bacterial suspension
was centrifuged at 34006g (5810R, Eppendorf AG, Hamburg,
Germany) for 20 min at 4uC, the supernatant discarded, and the
pellets washed with 100 ml of phosphate-buffered saline (PBS),
using the same centrifugation protocol. The supernatant was
discarded, the bacteria were resuspended in sterile 0.9% NaCl
solution, and the concentration of bacteria was determined
spectrophotometrically (Genesys 20, Thermo Scientific, Waltham,
MA, USA). For eBeam dose identification experiment, 25 ml of
bacterial suspensions of either approximately 16108 (concentra-
tion 1) or 16109 CFU/ml (concentration 2) were double-bagged
in heat-sealed sacs with no headspace, sealed inside a 95-kPa
transport bag (Therapak, Duarte, CA, USA), and exposed to
irradiation doses ranging from 0 to 7 kGy (in integer-unit doses)
using a 10-MeV, 18-kW linear accelerator. Alanine dosimeters
were used to verify the delivered eBeam dose. The interaction of
ionizing radiation with alanine releases free radicals [33], which
were measured by electron paramagnetic spin spectroscopy (E-
scan, Bruker BioSpin, Corp., Billerica, MA, USA). Twenty-five ml
of non-irradiated bacteria were inactivated for 30 min in a water
bath at 85uC, and were used as the heat-inactivated negative
control. After irradiation, quantitative culture was performed to
determine the concentration of replicating R. equi in each
irradiated sample, and to calculate the D10-value, the dose
required for 90% reduction of the initial population [40].
Experiments were conducted in triplicates, performed on 3
different days. For vaccine preparations administered to foals,
eBeam irradiated R. equi were cultured on days 1, 3, 5, 7, and 14
post-irradiation to confirm absence of bacterial replication.
Cell wall integrity of irradiated R. equi
The immunogenic proteins of R. equi are expressed on the
surface of the bacterium [34]; therefore, maintaining cell wall
integrity is important for retaining the immunogenicity of a whole
organism. Bacteria were grown as described above, and were
eBeam irradiated at the minimum dose that effectively inactivated
all microorganisms for the bacterial concentration; live and heat-
inactivated R. equi were prepared as positive and negative
controls, respectively. Samples were kept at 4uC for 12 h, and 1,
2, and 4 weeks after either irradiation or heat-inactivation. Two
methods were used to determine whether the bacterial cell wall
was intact. The first was a fluorescence-based assay (LIVE/DEAD
BacLight bacterial viability kit, Molecular Probes, Inc., Eugene,
OR, USA), which utilizes a mixture of SYTO 9 green-fluorescent
nucleic acid stain that stains all bacteria, and propidium iodide
that only penetrates damaged membranes [35], used according to
the manufacturer’s instructions. Briefly, bacterial samples were
treated with either PBS (does not damage the integrity of the cell
wall) or 70% isopropyl alcohol (should cause damage to the cell
wall). Then, a series of tubes containing a mixture with
percentages of PBS treated:alcohol treated bacteria (0:100,
10:90, 50;50, 90:10, 100:0) were prepared. Samples were
transferred to a 96-well flat-bottom microplate and mixed with
staining solution. Fluorescence of both SYTO 9 green and
propidium iodide were measured in each well with excitation
wavelength at 485 and 530 nm, respectively, using a microplate
reader (Synergy 2, Biotek, Winooski, VT, USA). A ratio of green/
red fluorescence was calculated (Gen5, Biotek, Winooski, VT,
USA) and plotted against the percentage of PBS treated:alcohol
treated bacteria. The second method was transmission electron
microscopy (TEM) of irradiated samples, heat-inactivated, and live
R. equi at 12 h, and 1, 2, or 4 weeks after processing. Bacterial
cells were fixed in 2% glutaraldehyde, 3% formaldehyde in 0.1 M
sodium cacodylate buffer, then post-fixed with 1% osmium
tetroxide and 0.5% potassium ferrocyanide, dehydrated in an
ascending alcohol series, and embedded in epoxy resin. Ultrathin
sections of the cells were examined with an FEI Morgagni 268
transmission electron microscope at an accelerating voltage of
80 kV. Digital images were acquired with a MegaView III camera
operated with iTEM software (Olympus Soft Imaging Systems,
Germany), and subsequently post-processed with Adobe Photo-
shop.
Study animals
Thirty-four healthy Quarter Horse foals and their respective
dams were used for this study. All foals had age-appropriate results
of complete blood count on day 2 of life, and had adequate
transfer of passive immunity as assessed by a commercially-
available qualitative immunoassay for serum concentration of total
IgG (SNAP test; IDEXX, Inc., Westbrook, ME, USA). All foals
were monitored daily by technical staff and twice weekly by a
veterinarian, and remained in good health without clinical signs of
disease throughout the study. Individual foals were randomly
assigned to the following groups: 1) EBRE 1 group (n = 9) which
received 261010 CFUs of R. equi inactivated by 4 kGy of eBeam
radiation in 100 ml of saline adjuvanted with 100 mg of cholera
toxin B subunit (CTB, List Biological Laboratories, Campbell, CA,
USA); 2) EBRE 2 group (n = 10) which received 161011 CFUs of
R. equi inactivated by 5 kGy of eBeam radiation in 100 ml of
saline adjuvanted with 100 mg of CTB; 3) Saline (negative)
control group (n = 9) which received 100 ml of saline adjuvanted
with 100 mg of CTB; and, 4) LVRE (positive) control group (n = 6)
which received 161010 CFUs of live R. equi in 100 ml of saline.
All treatments were administered enterally with a nasogastric tube
on days 2, 9, 16, and 23 of life. Physiological saline (NaCl 0.9%)
was used as a diluent for eBeam vaccines, live bacteria, and the
negative control.
eBeam R. equi Vaccine
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Sample collection
Samples were collected from foals on day 2 (prior to
vaccination) and on day 32 of life. For the broncho-alveolar
lavage (BAL) procedure, a 3-meter endoscope disinfected with
glutaraldehyde prior to use was passed via the nose into the lungs,
until the tube became gently lodged in a bronchus. Sterile saline
(30 ml) was instilled into the lung via the endoscope’s infusion
channel, followed by 20 ml of air to flush, and immediately
aspirated to recover at least 15 ml of fluid.
Naso-pharyngeal samples were collected by inserting a 16-inch
cotton swab pre-moistened with 3 ml of sterile saline in the nasal
ventral meatus. The naso-pharyngeal area was swabbed, the liquid
was manually squeezed from the swab using a 35-ml syringe into a
tube, and samples were frozen at 280uC until assayed.
Blood was collected from a jugular vein into tubes: 5 ml of
blood were collected into a tube without anticoagulant and
centrifuged at 30006g for 5 min to harvest serum, which was
separated and frozen at 280uC until assayed, and 16 ml of blood
was collected into tubes with sodium heparin as an anticoagulant
for isolation of peripheral blood mononuclear cells (PBMCs).
Mammary secretions and serum from the foals’ respective dams
were collected on day 2 postpartum (PP) for assessment of
maternal antibodies. Mares and foals are naturally exposed to R.
equi from the environment [36]; therefore, a considerable level of
antibody response was expected from the tested mares and foals
from natural exposure.
Cell-mediated immune response
The cell-mediated immune (CMI) response to vaccination was
assessed by interferon- c (IFN-c) production by PBMCs following
specific stimulation with eBeam inactivated R. equi. PBMCs were
isolated using Ficoll-Paque gradient separation (GE Healthcare,
Piscataway, NJ, USA) and carbonyl iron (Sigma-Aldrich, St. Louis,
MO, USA), resuspended in RPMI-1640 media (Gibco, Life
Technologies, Grand Island, NY, USA) with 15% fetal bovine
serum (Gibco, Life Technologies, Grand Island, NY, USA) and
1.5% penicillin-streptomycin (Gibco, Life Technologies, Grand
Island, NY, USA), and cultured for 48 h at 37uC with 5% CO2
with either media only, the mitogen ConA (positive control; 5 mg/
ml, Sigma-Aldrich, St. Louis, MO, USA), or eBeam inactivated R.
equi (multiplicity of infection of 10). After 48 h, supernatants from
each group were harvested, centrifuged at 3006g, and frozen at
280uC until examined for IFN-c production using an equine IFN-
c enzyme linked immunosorbent assay (ELISA) kit (Mabtech Inc.,
Mariemont, Ohio, USA) according to manufacturer’s instructions.
Optical densities (OD) were determined using a microplate reader
Synergy 2 (Biotek, Winooski, VT, USA), and standard curves were
generated and IFN-c concentrations in each sample were
calculated for each isotype using the software Gen 5 (Biotek,
Winooski, VT, USA).
Mucosal and systemic humoral immune responses
Mucosal humoral immune responses were assessed by quanti-
fying total and R. equi-specific IgA and IgG isotypes IgG1, IgG3/5,
and IgG4/7 in BAL fluid, and total and R. equi-specific IgA in
naso-pharyngeal swab eluates. Systemic humoral response was
assessed among foals by quantifying serum concentrations of total
and R. equi-specific IgA and IgG isotypes (IgG1, IgG4/7, IgG3/5).
Concentrations of total IgA and IgG isotypes (IgG1, IgG3/5, and
IgG4/7) were determined by ELISA using a commercial kit (Bethyl
Laboratories, Montgomery, TX, USA) according to manufactur-
er’s instructions. Reference serum (Bethyl Laboratories, Mon-
tgomery, TX, USA) was added for the positive controls and to
establish standard curves, and dilution buffer was used as blank.
Optical densities were determined by using a microplate reader.
Standard curves were generated and immunoglobulin concentra-
tions in each sample were calculated for each isotype using the
software Gen 5.
For determination of R. equi-specific IgA and IgG isotypes we
used a protocol described previously [37]. Briefly, ELISA plates
(Maxisorp, Nalge Nunc International, Rochester, NY) were coated
with 2.5 mg/ml of R. equi antigen diluted in coating buffer
(Carbonate-bicarbonate buffer, Sigma-Aldrich, St. Louis, MO)
overnight at 4uC. The protocol for preparation of R. equi antigen
has been described previously [38], except R. equi strain 5–331
was used in this study. Plates were washed five times with Tris-
buffered saline (TBS) with 0.005% Tween 20, blocked with 200 ml
TBS 1% bovine serum albumin for 30 min at room temperature
(RT), and washed again. Two-fold serial dilutions of serum and
mammary secretions samples from study foals, positive control R.
equi hyperimmune plasma (Mg Biologics, Ames, IA), and negative
control fetal horse serum (Biowest, Miami, FL, USA) were added
in duplicates to the wells and incubated for 60 min at 22uC. Both
BAL fluid and naso-pharyngeal (NP) swab eluates were used
undiluted. After another washing, goat anti-horse IgA, IgG1, or
IgG3/5 peroxidase conjugated, or sheep anti-horse IgG4/7
peroxidase conjugated (Bethyl Laboratories, Montgomery, TX)
were added to the wells and incubated for 60 min at RT. Plates
were washed again, and TMB One Component HRP Microwell
Substrate (Bethyl Laboratories, Montgomery, TX) was added to
the wells and incubated for 15 min at RT in the dark. The
reaction was stopped by adding sulfuric acid solution to the wells.
Optical densities were determined by using a microplate reader.
Relative quantities for day 2 and day 32 samples were obtained by




The ratio of the relative quantities on day 32 to the relative
quantities on day 2 was used to describe the relative increase/
decrease of antibodies following vaccination.
Data Analysis
Analysis of growth curves and cell wall integrity fluorescence
data were performed using linear mixed-effects models with
experimental replicates modeled as random effects [39]. The D10-
value was calculated from the negative inverse of the slope from
the linear mixed-effects regression of the irradiation dose on the
logarithm10 of the microbial population. [40]. Transmission
electron microscopy data were descriptive only.
Foal data were analyzed using the ratio of relative quantities on
day 32 to relative quantities on day 2 of life (baseline) of
immunoglobulins or IFN-c concentrations, or the proportion of
foals that had an increase in these relative quantities. When
appropriate, data were log10-transformed to ensure they met the
assumptions underlying the modeling strategy.
Ratio data were analyzed using a generalized linear model with
concentrations as the outcome variable and study group as the
independent variable of interest. Model fit was assessed by
examining diagnostic plots of residuals. Post-hoc pair-wise
comparisons among groups were made using the method of Sidak
[41]. Proportions of foals with increased immunoglobulin isotypes
were compared among groups using Fisher’s exact test.
Association (correlation) between immunoglobulin concentra-
tion in mare serum and mammary secretions immunoglobulins,
eBeam R. equi Vaccine
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and mare mammary secretions and NP swab eluates IgA were
made using linear regression analysis. Comparisons of immuno-
globulin concentrations among treatment groups were performed
using Kruskal-Wallis testing. All analyses were conducted using S-
PLUS (Version 8.0; Insightful, Inc.) and R (Version 2.12.1; R
Statistical Project) and a significance level of P,0.05.
Results
Effects of eBeam irradiation on R. equi
The doses required to prevent replication of R. equi at
concentrations of 16108 and 16109 CFU/ml were 4 and
5 kGy, respectively (Fig. 1). The D10-values estimated for R. equi
strain 5–331 in 0.9% NaCl exposed to 10-MeV, 18-kW eBeam
irradiation for the 2 concentrations were similar (0.48 [0.37 to
0.69] and 0.53 [0.47 to 0.61]); approximately 0.505 kGy) and did
not differ significantly (P.0.05).
The green/red fluorescence ratio increased significantly (P,
0.05) with the percentage of intact bacteria in all groups except the
heat-inactivated group (Fig. S1A, B, C and D), indicating that
eBeam irradiation did not damage bacterial membrane integrity
but that heat-inactivation did. Using TEM, the overall integrity of
the outer bacterial cell wall of all treated groups was preserved
(Fig. S2A, B, C, and D). Changes affecting the wall were confined
to the layered cell wall (LCW) of all groups, and were more severe
among bacteria of heat-inactivated groups suggesting a more
severe compromise of the cell wall integrity (consistent with the
fluorescent-based results). The internal cell contents were only
morphologically affected in bacteria of the heat-inactivated group.
Noticeable changes included enlarged nuclear areas that were
admixed with a filamentous material and inconspicuous glycogen-
like deposits (Fig. S2D).
Systemic immune response
Cell-mediated immune response. Stimulation with ConA
significantly (P,0.05) stimulated IFN-c production in cultured
PBMCs from foals from all treatment groups on both days 2 and
32 relative to unstimulated cells, and stimulation with eBeam
irradiated R. equi resulted in significantly greater IFN-c produc-
tion on day 32 (P,0.05) relative to unstimulated control (media
only) (Fig. S3). The IFN-c response was significantly (P,0.05)
greater for foals in the LVRE, EBRE 1, and EBRE 2 groups than
for foals in the saline control group (Fig. 2).
Humoral immunity. Serum concentrations of total IgA,
IgG4/7, and IgG3/5 decreased significantly with age for foals in all
Figure 1. Survival curves for R. equi samples in 0.9% NaCl irradiated with eBeam doses ranging from 0 to 7 kGy. Survival curve for
Concentration 1 (16108 CFU/ml) is indicated by the symbol#; Survival curve for Concentration 2 (16109 CFU/ml) is indicated by the symbol6; *0
represents true 0 and not 100 = 1.
doi:10.1371/journal.pone.0105367.g001
eBeam R. equi Vaccine
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groups (Fig. S4); however, there were no significant differences in
the decline of total immunoglobulins among groups.
There were no significant differences among groups in values of
the day 32-to-day 2 ratio of R. equi-specific serum IgA (Fig. 3A);
however, the ratios were significantly (P,0.05) less than 1 for all
groups. The day 32-to-day 2 ratios of serum IgG1 and IgG4/7 were
significantly (P,0.05) greater for the LVRE group than other
groups (Fig. 3B and C); there were no other significant differences
among groups. Similarly, the ratios were significantly (P,0.05)
greater for the LVRE group than the 2 vaccine groups (but not
controls; Fig. 3D). Note that the magnitudes of increase were
small.
Mucosal humoral immune response
Naso-pharyngeal samples. Total IgA concentration in
naso-pharyngeal samples were increased for all but 1 foal;
however, there were no significant differences among groups in
either the relative magnitude of increase from day 2 to day 32
(Fig. 4A) or the proportion of foals that had increased IgA
following vaccination (Figure 4B), although the EBRE2 and
LVRE groups tended to be increased. Although the relative
increase of R. equi-specific IgA in NP samples tended to be greater
for the EBRE2 and LVRE groups (Fig. 4B), there were no
significant differences among groups.
The proportions of foals that had increased R. equi-specific IgA,
however, differed significantly among groups (P = 0.0223; Fisher’s
exact test; Fig. 4D). Post-hoc specific pair-wise comparisons
indicated that the proportion of foals in the EBRE2 group that
had increased R. equi-specific IgA was significantly (P,0.05)
greater than that of the saline controls (Fig. 4D).
BAL fluid. The ratio of total and R. equi-specific IgA and IgG
isotypes for day 32 relative to day 2 were significantly (P,0.05 for
all) greater than 1 for all groups, indicating a significant increase
with age (Fig. S5); however, there were no significant differences
among groups in the values of these ratios. No significant
association was observed in either total or R. equi-specific IgA
between samples of BAL fluid and NP swabs from individual foals
(Fig. S6).
Figure 2. Ratio of IFN-c concentration in culture media of eBeam inactivated R. equi-stimulated isolated peripheral blood
mononuclear cells. Relative quantities on day 32 relative to day 2 (log10-transformed) from 34 foals in 4 treatment groups: 1) Saline: enteral
adjuvant only controls (N = 9); 2) EBRE 1: foals receiving 161011 R. equi eBeam irradiated with 4 kGy enterally (N = 10); 3) EBRE 2: foals receiving
261010 R. equi eBeam irradiated with 5 kGy enterally (N = 9); and, 4) LVRE: foals receiving 161010 live, virulent R. equi enterally (N = 6). Bars with
differing letters indicate significant (P,0.05) differences among groups.
doi:10.1371/journal.pone.0105367.g002
eBeam R. equi Vaccine
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Maternal Influence
All mares had detectable total and R. equi-specific immuno-
globulins of all classes in both mammary secretions and serum.
There was a significant (P,0.05) correlation between mammary
secretions and mare serum for total and R. equi-specific IgA, IgG1,
IgG4/7, IgG3/5, except for total concentrations of IgG1 and
IgG4/7; however, no differences among their respective foals
treatment group were observed (data not shown).
Because mammary secretions and mare serum concentrations
were correlated for most isotypes, and because we did not have
access to colostrum (produced in the first 24 h PP), we studied the
correlation of immunoglobulins in mammary secretions with that
of foal serum. There was a significant (P,0.05) positive association
for IgA and a tendency (0.05,P,0.11) for a positive association
for IgG4/7 and IgG3/5 between mammary secretions and foal
serum on day 2; there was no apparent association for IgG1 (Fig.
S7). No significant differences among vaccine/treatment groups
were observed. There was a significant (P,0.05) correlation
between mare’s mammary secretions concentration and foals NP
swab concentrations for both total and R. equi-specific IgA on day
2 of life (data not shown); however, there was no significant
difference among vaccine/treatment groups.
Discussion
The objectives of this study were to render R. equi non-
replicating with eBeam irradiation and to examine the immuno-
genicity of the eBeam irradiated R. equi administered intragastri-
cally to foals. Replicability of R. equi was inversely related to
eBeam irradiation dose (Fig. 1), as previously reported for other
microorganisms including Escherichia coli K-12 [42], Bacillus
atrophaeus [43], and avian influenza virus [29]. As expected, a
higher dose of irradiation was required to completely inhibit
replication of a higher concentration of R. equi. Thus, the dose of
irradiation for a vaccine preparation would need to be empirically
established for the target bacterial concentration. Depending on
the bacterial growth phase, a higher dose may be needed for
complete inhibition of bacterial replication because bacterial cells
in logarithmic growth phase can have multiple copies of their
genomes per cell [44].
At the doses selected, outer cell wall integrity appeared to be
conserved (Fig S1 and S2). We observed similar fluorescence ratios
for both concentrations of irradiated bacteria tested and live
samples for all time-points (day 1, weeks 1, 2, and 4), whereas the
heat-inactivated samples were considered damaged at all time-
points (Fig S1). This finding was anticipated because eBeam
irradiation was expected to damage the bacterial DNA [44], but
damage to the cell wall might be dose-dependent and conse-
quently titratable. For example, eBeam irradiation of spores of
Bacillus spp. caused membrane disruption with cytoplasm leakage
when high doses (i.e.,$10.4 kGy) were used but not at lower doses
[45]. We did not, however, evaluate bacterial structure in samples
irradiated with . 5 kGy in our study. Using TEM (Fig S2), all
control and irradiated samples preserved the overall structural
Figure 3. Mean Ratio of R. equi-specific IgA and IgG isotypes on serum samples from foals. OD on day 32 relative to day 2 (log10-
transformed) from 34 foals in 4 treatment groups as described in Fig. 2. Bars with differing letters indicate significant (P,0.05) differences among
groups. A) R. equi-specific IgA; B) R. equi-specific IgG1; C) R. equi-specific IgG4/7; D) R. equi-specific IgG3/5.
doi:10.1371/journal.pone.0105367.g003
eBeam R. equi Vaccine
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integrity of the cell wall [46], meaning that changes in the cell wall
indicative of destruction or perforation of the bacterial cell wall
were not observed. However, morphologic changes affecting
ultrastructural components of the cell wall (e.g., the layered cell
wall) and internal structures (e.g., nuclear area and glycogen-like
deposits) were observed. Although variation in severity of changes
involving the ultrastructural components of the cell wall was found
between the irradiated and heat-inactivated groups, morphologic
changes in internal structures only were detected in the heat-
inactivated bacteria. Preservation of the cell wall integrity after
eBeam irradiation has also been shown for Paracoccidioides
brasiliensis [47], and membrane damage of Bacillus spp. spores
was observed only at high doses of eBeam irradiation [45].
Although the evaluation of the ultrastructure in our study did not
reveal changes in the cell wall indicative of perforation or
destruction of the cell in any of the treatment groups, data from
the fluorescence assay, coupled with the presence of more severe
ultrastructural changes affecting the layered cell wall of heat-
inactivated bacteria, indicate that the cell wall of heat-inactivated
bacteria were more severely compromised relative to the other
treatment groups. For this study, we used a heat-inactivation
protocol of 85uC for 30 min. Other heat-killing protocols using
more prolonged exposure, higher temperatures, or both likely
would have caused more pronounced changes in the R. equi
ultrastructure. Overall, we observed that eBeam inactivation
resulted in better maintenance of normal membrane integrity and
structure than heat inactivation.
We observed that these structurally intact but non-replicating
bacteria were immunogenic in neonatal foals. We chose to
evaluate immune responses during the first month of life on the
basis of evidence that natural infection with R. equi generally
occurs early in life [48,49]. We elected to use ratios (day 32 values
relative to day 2) because of considerable variation in absolute
values among individual foals and between ages (e.g., declining
total antibody concentrations or increasing IFN-c production with
age).
Cell-mediated immune responses are of irrefutable importance
to immunity to intracellular pathogens, including R. equi [50].
Neonatal foals, however, are known to have age-related impaired
ability to produce IFN-c [51,52], which is essential for activating
macrophages to kill intracellular R. equi [53]. Consistent with
previous findings, we observed that IFN-c expression by PBMCs
Figure 4. Mean ratios of total and R. equi-specific IgA in naso-pharyngeal samples. Relative quantities on day 32 relative to day 2 (log10-
transformed) of IgA from 34 foals in 4 treatment groups as described in Fig. 2. Bars with differing letters indicate significant (P,0.05) differences
among groups. A) Mean ratio (95% confidence interval) concentration total IgA; B) Mean ratio OD R. equi-specific IgA; C) Proportion of foals with
increase in total IgA from day 32 relative to day 2; D) Proportion of foals with increase in R. equi-specific IgA from day 32 relative to day 2.
doi:10.1371/journal.pone.0105367.g004
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increased with age (both basal and stimulated expression; Fig 2).
More importantly, neonatal foals vaccinated with either dose of
eBeam irradiated R. equi produced significantly greater IFN-c in
response to stimulation with R. equi antigens (lysate) than did
controls, and this indicator of CMI responses was similar to that
generated by the LVRE group (the positive control group; Fig 2
and Fig S3). These results indicate that enteral mucosal
vaccination with irradiated bacteria can stimulate systemic CMI
responses in neonatal foals in the face of maternal transfer of
antibody (including antibodies against R. equi) and natural
exposure to environmental R. equi similar to those induced by
enterally-administered live R. equi. Thus, even immunologically
naı¨ve newborn foals can be primed to fight intracellular pathogens
such as R. equi at an early age. The results from the LVRE group
are further important because they extend our knowledge of CMI
responses to enteral administration of live, virulent R. equi, the
only approach repeatedly demonstrated to protect foals against
subsequent experimental intrabronchial challenge with virulent R.
equi. Alternatively, a non-specific immune response could be
occurring in vitro, through stimulation of innate immune cells
(such as monocytes or macrophages). Nonetheless, vaccination of
foals with the eBeam inactivated R. equi vaccine induced an
immune response that was significantly different from foals
receiving saline plus adjuvant, but similar to that of the LVRE
group, demonstrating the immunomodulatory effect of this
vaccine in newborn foals, regardless of the cell source of the
IFN-c produced.
The concentration of total immunoglobulins of all isotypes in
foal serum decreased with age but there was no significant
difference among vaccine/treatment groups (Fig. 3 and Fig S4).
Age-related decline in maternal antibody has been demonstrated
in foals [54,55], and was expected as a result of consumption and
catabolization of maternally-derived immunoglobulin [55]. Foals
from the LVRE group had significantly higher day 32-to-day 2
ratios of serum R. equi-specific IgG1 and IgG4/7 compared to
other groups, and of IgG3/5 compared to both groups of
vaccinates (but not saline control foals). The importance of these
findings remains to be determined. Reported associations of
specific IgG isotypes with protection against R. equi are
inconclusive and conflicting. Initially, it was suggested that IgG1
was expected to be protective because it represented a Th1
isotype, whereas and IgG3/5 and IgG4/7 were Th2 isotypes [56],
while both IgG1 and IgG4/7 interact with Fc receptors on effector
cells and activate complement [57]. Subsequent studies, however,
have indicated that IgG isotype dominance is not indicative of
protection against R. equi in foals [17]. The magnitude of
observed increase was modest for IgG3/5 and IgG4/7, with neither
isotype for the ratio of day 32-to-day 2 being significantly greater
than 1. Nonetheless, enteral administration of eBeam inactivated
bacteria did not result in similar systemic antibody responses as
enteral administration of live R. equi. The relevance of our results
for increased ratios for R. equi-specific IgG1 and IgG4/7 induced
in the LVRE group to protection against infection is an important
consideration that remains to be determined.
Nasal mucosal R. equi-specific IgA appeared to be increased
among foals in the higher-dose vaccine group (EBRE 2) than
saline controls; the increase for the EBRE 2 foals was most similar
to the LVRE group (positive controls) in magnitude of the ratio
and proportion of foals whose ratio increased between days 2 and
32 (Fig 4). IgA is an important immunoglobulin at mucosal
surfaces that functions primarily as a neutralizing antibody, but
can also opsonize and activate complement [58]. Infection with R.
equi in foals is thought to occur by inhalation of the bacterium
[50], so IgA in nasal secretions may be an important barrier to R.
equi infections in nasal passages by either neutralizing inhaled
bacteria or by opsonizing them for subsequent phagocytosis and
killing by neutrophils in the lungs. Although CTB is an adjuvant
known to induce IgA responses at mucosal surfaces [59], we
nonetheless observed a significantly higher proportion of foals
from the EBRE2 group with increased R. equi-specific nasal IgA
compared to the saline control group. We observed that both total
and R. equi-specific nasal IgA amounts increased significantly with
age, consistent with what has been reported previously for total
IgA [49]; to our knowledge, this is the first such report for R. equi-
specific nasal IgA. These findings indicate nasal mucosal immunity
against R. equi may be relatively diminished in newborn foals,
possibly rendering them more susceptible infection. Our findings
differ from a study of Streptococcus equi subspecies equi, in which
an adequate passive transfer of S. equi-specific antibodies was
observed soon after colostrum intake [60]. The reasons for this
discrepancy between studies is unclear, but might be attributable
to differences in the host-agent interaction of the 2 organisms,
differences in background exposure and vaccination of mares, and
differences between studies in methods for evaluating antibody
concentrations.
Because R. equi primarily causes pneumonia in foals, we
evaluated immunoglobulin concentrations in BAL fluid of study
foals (Fig S5 and S6). Similar to IgA from NP samples, we
observed age-related increases (i.e., day 32-to-day 2 ratios
significantly . 1) in BAL fluid concentrations of total and R.
equi-specific IgA, IgG1, IgG3/5, and IgG4/7; however, no
significant differences were observed among vaccine/treatment
groups for any isotypes. As was observed in the foals of this study,
IgG and not IgA is the most abundant antibody in human BAL
fluid [61]. The concentrations of R. equi-specific immunoglobulins
of all isotypes in BAL fluid were very low, and in some instances
undetectable, especially on day 2. We thus repeated analyses after
concentrating the BAL fluid but results were essentially identical to
those presented for the original analysis (data not shown). It is
unclear to what extent our BAL technique affected our results. We
chose to use a low-volume BAL (30 ml) on the basis of previous
research in sheep, in an attempt to yield more concentrated BAL
fluid [62–64]. Larger volumes (such as 180 ml [65] or 500 ml [14])
are used to obtain BAL samples from foals. Conceivably, a larger
lavage volume might have provided greater contact with lung
tissue or yielded more immunoglobulins following concentration of
a larger volume.
Both total and R. equi-specific antibodies of all isotypes were
identified in both mammary secretions and serum from mares. It
has been shown in mares that the concentration of IgG antibodies
in mammary secretion decrease rapidly postpartum [66], and we
recognize that mammary secretion samples from day 2 PP are
likely different than colostrum ingested during the first 24 hours
PP; nevertheless, there were positive associations between all
immunoglobulin isotypes in the dams’ mammary secretions day 2
PP and foals serum and NP swab samples (Fig S7). One frequent
concern regarding vaccination of newborns is the presence and
interference of maternal antibodies that could neutralize the
vaccine, impairing the newborn’s response to the vaccine. We did
not observe this in the present study; in fact, we observed the
generation of a CMI response in spite of the presumed presence of
maternal antibodies. This situation has also been demonstrated
with vaccination against measles in 6-month-old infants [67],
where there was significant generation of IFN-c producing CD4+
T cells in spite of the presence of maternal antibodies,
demonstrating that mucosal vaccination in neonates can be
efficacious in priming the immune system.
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Our study has a number of limitations. First, intra-gastric
administration of 4 doses of vaccine is impractical for large-scale
use at farms. Arguably, it might be considered less cumbersome,
labor-intensive, and risky for foals than the accepted and
widespread use of transfusion of hyperimmune plasma to foals to
reduce the incidence of R. equi pneumonia [5]. A second
limitation is that we determined the IFN-c concentration using
supernatant of cultured PBMCs stimulated in vitro with either
ConA or eBeam inactivated R. equi. We are aware that different
populations of cultured cells could be producing IFN-c; neverthe-
less, we were able to demonstrate that vaccinated foals responded
better than saline control foals to eBeam inactivated R. equi,
irrespective of the cell source, and in a similar way to foals
receiving LVRE, known for inducing protective immune responses
against R. equi challenge. Another limitation is that we did not
evaluate efficacy of the vaccine. We also need to point out that we
have not optimized the vaccine dose nor have we optimized the
choice and the concentration of adjuvants. We recognize that no
vaccine is proven efficacious until protecting foals against disease
from the pathogen of interest. On the basis of our evidence that
the vaccine is indeed immunogenic, we have initiated challenge
studies of this candidate vaccine.
In summary, we demonstrate that eBeam can safely inactivate
R. equi, without compromising the cell wall integrity, for potential
use in vaccines. We also demonstrate that R. equi inactivated with
eBeam doses of either 4 or 5 kGy can be immunogenic in foals
when administered enterally with CTB as adjuvant.
Supporting Information
Figure S1 Ratio of green/red fluorescence using the
fluorescence-based LIVE/DEAD BacLight bacterial via-
bility kit for Concentration 1 (approximately 16108
colony-forming CFU/ml; square) and Concentration 2
(approximately 16109 CFU/ml; triangle) eBeam irradi-
ated, live (diamond shape) and heat-inactivated samples
(circle). A) Day 1, B) Week 1, C) Week 2, and D) Week 4 of
storage at 4uC.
(TIF)
Figure S2 Ultrastructure of live, heat-inactivated, and
eBeam irradiated R. equi. a) Live group, week 4. Normal
morphologic appearance of the nuclear area (NA). b) Concentra-
tion 2 eBeam irradiated, week 4. Similar morphologic appearance
of the NA compared to the live bacterium of image ‘‘a’’. The
arrows are indicating invaginations of the layered cell wall. c)
Heat-inactivated group, day 1. Nuclear area (NA) markedly
vacuolated and has increased electron lucency. d) Live group, day
1. Closer magnification of a live bacterium depicting the
localization of the layered cell wall (black arrows) and of
glycogen-like material (white arrowheads). e) Concentration 2
eBeam irradiated with 5 kGy, day 1. Closer view of radiated
bacteria demonstrating intact layered cell walls (black arrowheads),
invaginations of the layered wall (arrow), and preservation of
glycogen-like material (white arrowheads). f) Heat-inactivated, day
1. Closer magnification of a heat-killed bacterium that presents
large areas where the layered cell wall is either not present (arrows)
or presents marked invagination/coiling (arrowheads). Note the
vacuolated nuclear area (*), and inconspicuous glycogen-like
material. Concentration 2 (b) and Live bacteria (a) remains intact
after 4 weeks of refrigeration, whereas heat-inactivated (c) bacteria
denote changes after 12 h of refrigeration.
(TIF)
Figure S3 Effects of stimulus (ConA, Concavalin A 5 ug/
ml; Control, saline [unstimulated control]; and, eBeam
irradiated R. equi [MOI 1:10]) on concentration of IFN- c
in cell culture supernatant of foals at ages 2 days (panel
A) or 32 days (panel B), from all treatment groups
combined. At both ages, concavalin A stimulated a significant
increase in IFN- c concentration (pg/ml). Within a panel, differing
letters indicate significant differences stimuli. Between panels,
different numbers indicate differences between ages.
(TIF)
Figure S4 Mean Ratio of total IgA and IgG isotypes
concentration from foal serum. Concentration on day 32
relative to day 2 (log10-transformed) from 34 foals in 4 treatment
groups: 1) Saline: enteral adjuvant only controls (N = 9); 2) EBRE
1: foals receiving 161011 R. equi eBeam irradiated with 4 kGy
enterally (N = 10); 3) EBRE 2: foals receiving 261010 R. equi
eBeam irradiated with 5 kGy enterally (N = 9); and, 4) LVRE:
foals receiving 161010 live, virulent R. equi enterally (N = 6); Bars
with differing letters indicate significant (P,0.05) differences
among groups. A) Total IgA; B) Total IgG1; C) Total IgG4/7;
D) Total IgG3/5.
(TIF)
Figure S5 Mean Ratio of total and R. equi-specific IgA
and IgG isotypes on BAL fluid from foals. Relative
quantities concentrations (total) and OD (R. equi-specific) on day
32 relative to day 2 (log10-transformed) from 34 foals in 4
treatment groups as described in Fig. S4. Bars with differing letters
indicate significant (P,0.05) differences among groups. A) Total
IgA; B) Total IgG1; C) Total IgG3/5; D) Total IgG4/7. E) R. equi-
specific IgA; F) R. equi-specific IgG1; G) R. equi-specific IgG3/5;
H) R. equi-specific IgG4/7.
(TIF)
Figure S6 Association between Mean Ratio R. equi-
specific IgA concentration from foal NP swab eluates
and BAL fluid. Relative quantities on day 32 relative to day 2
(log10-transformed) from 34 foals in 4 treatment groups as
described in Fig. S4. There was no significant association
(P = 0.5907; Pearson’s correlation coefficient = 0.0956) between
the BALF R. equi-specific IgA and the nasal R. equi-specific IgA
values for foals.
(TIF)
Figure S7 Association between mammary secretions
and foal serum samples on day 2 for R. equi-specific
immunoglobulins. A) IgA; the association was weak but
statistically significant (P,0.0001); B) IgG1; the association was
weak and not statistically significant (P = 0.1345); C) IgG4/7; the
association was weak but statistically significant (P,0.0001); D)
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